July 10, 2023 — Novartis announced that the US Food and Drug Administration (FDA) has approved a label update for Leqvio ...
January 4, 2022 — The U.S. Food and Drug Administration (FDA) has cleared Novartis' inclisiran (Leqvio), the first small ...
May 15, 2021 — The combination heart failure drug sacubitril/valsartan (Entresto) did not significantly reduce the rate ...
November 16, 2020 — Novartis announced results from two pooled post-hoc analyses of Phase III ORION-9, -10 and -11 ...
October 5, 2020 — The American College of Cardiology (ACC) says heart failure (HF) is a cardiovascular epidemic. In ...
September 4, 2019 – Novartis announced results from two new clinical trials evaluating improvement in heart structure ...
September 19, 2017 — The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain ...
February 9, 2016 — Cigna has entered into an outcomes-based contract with the pharmaceutical company Novartis for the ...
September 16, 2015 — The Institute for Clinical and Economic Review (ICER) has released a new report offering a ...
October 15, 2014 — Novartis Pharmaceuticals Canada Inc. revealed, in the largest heart failure study to date, that its ...